SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.58+0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (8826)7/15/2003 1:43:59 AM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
Erik,

As I mentioned early treatment approach for HRPC changed in last few years, by introduction of the taxotere as first line therapy. So, if SPPI want first line approach they would need to go against Taxotere, not prednisone. Which is very high risk. Platinum based drug as second line therapy may work, but can it compete with others (new) platinum drugs? Second, somehow I do not believe in good cytotoxic ORAL agent. TTP of few months and median survival few months extra does not give oral versus i.v. approach big advantage. At this point I am conservative on Satraplatin.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News